Company Filing History:
Years Active: 2021
Title: Silin Pang: Innovator in Medicinal Chemistry
Introduction
Silin Pang is a notable inventor based in Nanjing, China. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on isocitrate dehydrogenase inhibitors. His research focuses on developing chemical compounds that can effectively target specific enzymes associated with tumor growth.
Latest Patents
Silin Pang holds a patent for a chemical compound of an isocitrate dehydrogenase inhibitor, which is crucial for the treatment of tumors characterized by the presence of mutant IDH2. The patent details the chemical compound represented by formula I, along with its isomers, pharmaceutically acceptable salts, crystals, solvates, or prodrugs. The compound demonstrates a strong ability to inhibit mutant IDH2 enzyme activity and neoplastic cells, showcasing its potential in cancer prevention and treatment.
Career Highlights
Pang is currently associated with Nanjing Sanhome Pharmaceutical Co., Ltd., where he continues to advance his research in medicinal chemistry. His work has garnered attention for its potential applications in therapeutic settings, particularly in oncology.
Collaborations
Silin Pang collaborates with esteemed colleagues, including Yong Wang and Liwen Zhao, who contribute to his research endeavors. Their combined expertise enhances the development of innovative solutions in the pharmaceutical industry.
Conclusion
Silin Pang's contributions to medicinal chemistry, particularly through his patent on isocitrate dehydrogenase inhibitors, highlight his role as a key innovator in the field. His work not only advances scientific knowledge but also holds promise for future cancer therapies.